Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

NCT06369467 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Food Allergy

Interventions

DRUG: linvoseltamab
DRUG: dupilumab

Sponsor

Regeneron Pharmaceuticals